ClinicalTrials.gg
RecruitingNCT05893550Updated Jun 8, 2023

Omega-3 Supplementation to Both Parent and Adolescent

A Phase 3 interventional study of Smartfish Omega and Smartfish Fruit Juice Only in Behavior Problems, sponsored by Joint Child Health Project, Mauritius. Recruiting at 1 site in Mauritius. Open to participants aged 11 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-06-08.

Sponsored by Joint Child Health Project, Mauritius · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Jul 2023, 3 years 3 months ago, but the record still lists the study as recruiting.
  • Started Mar 2018; still recruiting 8 years 8 months later.
Phase
Phase 3
Study type
Interventional
Enrollment
800
Allocation
Randomized
Ages
11 Years to 50 Years
Sex
All
01

Study summary

The overarching, long-term goals are to develop a non-invasive biological approach to prevention of youth aggression, and ultimately adult violence.

The specific aims of this 2 x 2 randomized, double-blind, stratified, placebo-controlled trial of omega-3 supplementation to adolescents and caregivers are: (1) to investigate whether a nutritional intervention to adolescents and their parents can reduce externalizing behavior problems; (2) to examine the impact of a dual nutritional intervention to both parents and adolescents on adolescent externalizing behavior problems; (3) to identify mechanisms of action by which omega-3 supplementation impacts externalizing behavior in adolescents. It is expected that omega-3 supplementation will reduce adolescent behavior problems, and that dual supplementation to both the caregiver and adolescent will result in exponential improvements in adolescent behavior. A secondary prediction is that improvements in neurocognitive functioning will partially account for any behavioral improvements observed. Effects on scholastic ability are also explored.

Read the detailed description

Despite increasing evidence for a significant neurobiological basis to aggression, biological interventions have been largely side-stepped, despite the fact that violence is a global public health problem. An important need is to develop socially acceptable ways of bettering brain functioning to reduce adolescent behavior problems, a critical developmental stage for adult violence perpetration and mental health problems. This is the primary health challenge that this proposal aims to tackle. Our pilot data documents that omega-3, a long-chain fatty acid which is critical for brain structure and function, reduces behavior problems in children and adolescents six months after the end of supplementation. If it can further document support and extension of the pilot findings with dual supplementation to both parent and adolescent, and if the investigators can begin to identify the mechanisms of action underlying change, this can provide a new vista on biological interventions for adolescent externalizing problems that predispose to violence. The overarching, long-term goals are to develop a non-invasive biological approach to prevention of youth aggression, and ultimately adult violence.

The specific aims of this 2 x 2 randomized, double-blind, stratified, placebo-controlled trial of omega-3 supplementation to adolescents and caregivers are: (1) to investigate whether a nutritional intervention to adolescents and their parents can reduce externalizing behavior problems; (2) to examine the impact of a dual nutritional intervention to both parents and adolescents on adolescent externalizing behavior problems; (3) to identify mechanisms of action by which omega-3 supplementation impacts externalizing behavior in adolescents. It is expected that omega-3 supplementation will reduce adolescent behavior problems, and that dual supplementation to both the caregiver and adolescent will result in exponential improvements in adolescent behavior. A secondary prediction is that improvements in neurocognitive functioning will partially account for any behavioral improvements observed. Effects on scholastic ability are also explored.

The paradigm-shift that could influence clinical practice is the use of a biological intervention that is not solely focused on the adolescent, but which is also applied to the primary caregiver. To the investigators' knowledge, such dual supplementation has never been examined. From an epidemiological standpoint, if this dual intervention approach could reduce even modestly the overall level of aggressive and antisocial behavior in the community at large, there is the promise of enhancing child health and development with a clinical paradigm novel in the biological study of behavior problems. The study's significance extends beyond adolescent behavior problems, which predispose not just to later adult violence, but also a wide array of adult psychiatric disorders. These adult outcomes result in an enormous societal burden in terms of economic costs, reduced occupational functioning, social functioning, and quality of life for both victims and perpetrators, a burden which could be significantly ameliorated if the pilot findings are supported.

02

Conditions studied

  • Behavior Problems

Browse trials for

03

In context

Mental Disorders

1,740 studies on the registry are indexed under Mental Disorders; 348 are open to participants now.

This study's planned enrollment of 800 is above the median of 100 across 1,301 interventional studies indexed under Mental Disorders.

Browse Mental Disorders studies →

Lead sponsor

Joint Child Health Project, Mauritius is the lead sponsor of 2 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
11 Years to 50 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • adolescents between Age 11 and 18
  • willing to participate in a randomized control trial
  • parent participated in prior Mauritius Child Health Project

Exclusion criteria

Exclusion Criteria:

  • Allergy to fish or fish products
  • Intellectual disability
  • Use of fish oil supplementations in the past 6 months
05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
800 participants (estimated)

Study arms

  • Experimental
    Both Parent and child

    Smartfish Omega Both parent and child receive Omega-3 drink

    Dietary Supplement: Smartfish Omega

  • Experimental
    Parent Only

    Smartfish Omega Only the parent receives Omega-3 drink, child receives Placebo.

    Dietary Supplement: Smartfish Omega · Dietary Supplement: Smartfish Fruit Juice Only

  • Experimental
    Child Only

    Smartfish Omega Only the child receives Omega-3 drink, the parent receives placebo

    Dietary Supplement: Smartfish Omega · Dietary Supplement: Smartfish Fruit Juice Only

  • Placebo comparator
    Neither

    Smartfish Fruit Juice Only Neither parent nor child receives omega-3; both receive placebo (fruit juice).

    Dietary Supplement: Smartfish Fruit Juice Only

Interventions

  • Dietary supplementSmartfish Omega

    Fruit juice drink containing Omega-3: the experimental condition

  • Dietary supplementSmartfish Fruit Juice Only

    this is a fruit juice drink with no omega-3 added. it is the placebo condition

06

What researchers measure

Primary outcomes

  1. Change in behavior problems

    Behavior problems are assessed on a battery of measures with standardized units from parent and child reports. . Aggressive behavior, rule-breaking behavior, and attention problems will be assessed using the Youth Self-Report (YSR; Achenbach \& Rescorla, 2001). The fourth scale is the 10-item version of the Inventory of Callous-Unemotional Traits (ICU; Ray et al., 2016). The final two scales are the Reactive and Proactive Aggression scales of the Reactive and Proactive Aggression Questionnaire (Raine et al. 2006). To reduce variables to a more reliable and all-encompassing construct of antisocial behavior, and to avoid Type 1 error, a principal components analysis was conducted on these six measures. Factor scores will be saved using the regression method, with higher scores indicating higher child antisocial behavior. Factor scores over time will be assessed.

    Time frame: 0, 6, 12, 18 months

Secondary outcomes

  1. Change in neurocognitive functioning

    assessed from a neuropsychological test battery: standardized units. The Digit Forward, Digit Backward, Coding, and Arithmetic, Pairing, and Free Recall tests will be administered using the Wechsler Intelligence Scale for Children (WISC-III; Wechsler, 1991), together with the Trails A and Trails B tests.Factor scores will be saved using the regression method, with higher scores indicating higher cold EFs. Chganges in factor scores over time will be evaluated.

    Time frame: 0,6,12,18 months

  2. Change in substance use.

    smoking, alcohol, marijuana: standardized units. These will be assessed based on the Achenbach Adult Self-Report. Change over time will be evaluated.

    Time frame: 0, 6,12,18 months

07

Study locations

1 of 1 sites recruiting
  • Joint Child Health Project
    Quatre Bornes, Mauritius
    Recruiting
08

References and documents

Publications

  • Raine A, Liu J, Venables PH, Mednick SA, Dalais C. Cohort profile: The Mauritius Child Health Project. Int J Epidemiol. 2010 Dec;39(6):1441-51. doi: 10.1093/ije/dyp341. Epub 2009 Dec 7. No abstract available. PubMed 19995862 ↗

Related links

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Undecided

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jun 8, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05893550
Lead sponsor
Joint Child Health Project, Mauritius
Responsible party
Sponsor
First posted
Jun 8, 2023
Start date
Mar 5, 2018
Primary completion
Jul 31, 2023 (estimated)
Completion
Jul 31, 2023 (estimated)
Last update
Jun 8, 2023

Study contacts

Tashneem Mahoomed, BSc
Contact
jchp2010@gmail.com
00230 52524414
Shameemah Golamnobee, BSc
Contact
Gshamj@gmail.com
00230 4245516
Adrian Raine, D.Phil.
principal investigator · University of Pennsylvania
Tashneem Mahoomed, BSc
study director · Joint Child Health Project

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion